GlassScriptPhysician profile
Omid Rabbani
NPI 1033296587
$12,224.13
in general payments reported to CMS, 2019-2025
61 companies · $20.18 in 2025
The $20.18 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,637 · 2020: $2,237 · 2021: $2,313 · 2022: $2,785 · 2023: $3,148 · 2024: $84.11 · 2025: $20.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,252.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,541.47 | 2019-2024 | |
| Ucb, INC. | $700.30 | 2019-2023 | Briviact, Fintepla |
| Novartis Pharmaceuticals Corporation | $550.91 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $550.02 | 2019-2023 | Austedo Xr, Austedo |
| Amgen INC. | $471.13 | 2019-2025 | Aimovig, Uplizna |
| Sk Life Science, INC. | $443.64 | 2020-2023 | |
| Mdd US Operations, LLC | $436.79 | 2019-2023 | Apokyn |
| Amneal Pharmaceuticals LLC | $423.23 | 2019-2023 | Rytary |
| Biogen, INC. | $416.86 | 2019-2023 | Vumerity |
| Csl Behring | $390.09 | 2019-2024 | Hizentra |
| Emd Serono, INC. | $358.18 | 2019-2023 | Mavenclad |
| Allergan, INC. | $343.19 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $321.19 | 2019-2023 | Ultomiris |
| Acorda Therapeutics, INC | $319.22 | 2019-2023 | Ampyra, Inbrija |
| Sunovion Pharmaceuticals INC. | $287.70 | 2020-2022 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omid Rabbani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.